BE2016C018I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C018I2
BE2016C018I2 BE2016C018C BE2016C018C BE2016C018I2 BE 2016C018 I2 BE2016C018 I2 BE 2016C018I2 BE 2016C018 C BE2016C018 C BE 2016C018C BE 2016C018 C BE2016C018 C BE 2016C018C BE 2016C018 I2 BE2016C018 I2 BE 2016C018I2
Authority
BE
Belgium
Application number
BE2016C018C
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22821718&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BE2016C018I2 publication Critical patent/BE2016C018I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
BE2016C018C 2000-07-21 2016-04-07 BE2016C018I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22002100P 2000-07-21 2000-07-21
PCT/US2001/023104 WO2002008241A2 (fr) 2000-07-21 2001-07-20 Promedicaments a base d"analogues nucleotidiques de phosphonate et leurs methodes de selection et d"elaboration

Publications (1)

Publication Number Publication Date
BE2016C018I2 true BE2016C018I2 (fr) 2020-08-20

Family

ID=22821718

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C018C BE2016C018I2 (fr) 2000-07-21 2016-04-07

Country Status (37)

Country Link
US (10) US20020119443A1 (fr)
EP (3) EP2682397B1 (fr)
JP (4) JP4651264B2 (fr)
KR (2) KR100749160B1 (fr)
CN (2) CN1291994C (fr)
AP (1) AP1466A (fr)
AU (3) AU2001282941C1 (fr)
BE (1) BE2016C018I2 (fr)
BG (1) BG66037B1 (fr)
BR (1) BRPI0112646B8 (fr)
CA (3) CA2416757C (fr)
CY (2) CY2016008I1 (fr)
CZ (2) CZ304886B6 (fr)
DK (2) DK1301519T4 (fr)
EA (1) EA004926B1 (fr)
EE (1) EE05366B1 (fr)
ES (2) ES2536972T5 (fr)
FR (1) FR16C0013I2 (fr)
HK (2) HK1054238A1 (fr)
HR (2) HRP20160074B1 (fr)
HU (2) HU230960B1 (fr)
IL (1) IL153658A0 (fr)
IS (1) IS2985B (fr)
LT (2) LT2682397T (fr)
LU (1) LU93029I2 (fr)
MX (1) MXPA03000587A (fr)
NL (1) NL300803I2 (fr)
NO (6) NO336718B1 (fr)
NZ (3) NZ536942A (fr)
OA (1) OA12393A (fr)
PL (1) PL213214B1 (fr)
PT (2) PT1301519E (fr)
SI (2) SI1301519T1 (fr)
TR (1) TR200300055T2 (fr)
UA (1) UA75889C2 (fr)
WO (1) WO2002008241A2 (fr)
ZA (1) ZA200210271B (fr)

Families Citing this family (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
JP2005519983A (ja) * 2001-11-14 2005-07-07 バイオクリスト・ファマシューティカルズ インク． ヌクレオシド、その調製、及び、ｒｎａウイルスポリメラーゼの阻害剤としてのその使用
US7388002B2 (en) * 2001-11-14 2008-06-17 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
DE60315023T2 (de) * 2002-04-26 2008-04-03 Gilead Sciences, Inc., Foster City Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
CN105596356A (zh) * 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
WO2004096285A2 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Analogues anti-infectieux du phosphonate
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
AU2004233897A1 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
WO2004096287A2 (fr) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (fr) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7429565B2 (en) * 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2005044308A1 (fr) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Analogues phosphonates d'antimetabolites
US7427624B2 (en) * 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
EP1678322A2 (fr) 2003-10-24 2006-07-12 Gilead Sciences, Inc. Procedes et compositions pour l'identification des composes therapeutiques
BRPI0418031A (pt) * 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
KR20060127906A (ko) * 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-치환된 카보버와 아바카비어 유도체 및 ｈｉｖ와 ｈｃｖ항바이러스 활성을 갖는 관련 화합물
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
PT2204374E (pt) * 2003-12-30 2012-09-17 Gilead Sciences Inc Fosfonatos nucleosídeos e seus análogos para o tratamento de infecções com hpv
DE602005017131D1 (de) * 2004-01-21 2009-11-26 Gilead Sciences Inc Verwendung von adefovir oder tenofovir zur hemmung von mmtv-artigen viren im zusammenhang mit brustkrebs und primärer biliärer zirrhose
US8432394B1 (en) 2004-05-14 2013-04-30 Nvidia Corporation Method and system for implementing clamped z value interpolation in a raster stage of a graphics pipeline
US8411105B1 (en) 2004-05-14 2013-04-02 Nvidia Corporation Method and system for computing pixel parameters
US8416242B1 (en) 2004-05-14 2013-04-09 Nvidia Corporation Method and system for interpolating level-of-detail in graphics processors
US7079156B1 (en) 2004-05-14 2006-07-18 Nvidia Corporation Method and system for implementing multiple high precision and low precision interpolators for a graphics pipeline
CN103374041B (zh) 2004-06-08 2017-05-10 症变治疗公司 路易斯酸介导的环状酯的合成
SI2258376T1 (sl) * 2004-07-27 2019-04-30 Gilead Sciences, Inc. Analogi fosfonata spojin inhibitorjev HIV
JP2008535862A (ja) 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
EP1865967A4 (fr) * 2005-04-08 2011-02-09 Chimerix Inc Composes, compositions et methodes de traitement d'infections virales et autres troubles medicaux
CN100359315C (zh) * 2005-05-26 2008-01-02 林维宣 兽药残留能力验证样品及制备方法
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
CN100396689C (zh) * 2006-03-07 2008-06-25 中国医学科学院医药生物技术研究所 一组具有抑制hiv-1/hbv病毒复制活性的替诺福韦单酯化合物
AU2007254309B2 (en) 2006-05-16 2012-05-03 Gilead Sciences, Inc. Method and compositions for treating hematological malignancies
WO2008007392A2 (fr) 2006-07-12 2008-01-17 Matrix Laboratories Limited Procédé amélioré destiné à préparer du ténofovir
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2693176C (fr) * 2007-06-26 2015-02-03 Song Jin Systemes de traitement et de prevention des eaux d'exhaure acides et des agents contaminants halogenes
US8441497B1 (en) * 2007-08-07 2013-05-14 Nvidia Corporation Interpolation of vertex attributes in a graphics processor
US8993542B2 (en) * 2008-01-25 2015-03-31 Chimerix Inc. Methods of treating viral infections
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
EP2937356A1 (fr) 2008-04-25 2015-10-28 Cipla Limited Forme cristalline du ténofovir disoproxil et son procédé de préparation
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR20110065440A (ko) * 2008-07-02 2011-06-15 아이데닉스 파마슈티칼스, 인코포레이티드 바이러스 감염의 치료를 위한 화합물 및 제약 조성물
BRPI0915878A2 (pt) * 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (fr) 2008-12-23 2010-07-01 Pharmasset, Inc. Phosphoramidates de nucléosides
SG194404A1 (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2012011222A (es) 2010-04-01 2013-01-18 Centre Nat Rech Scient Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales.
EP2563367A4 (fr) 2010-04-26 2013-12-04 Chimerix Inc Méthodes de traitement d'infections rétrovirales et régimes posologiques associés
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CA2818853A1 (fr) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides destines a la therapie contre le virus de l'hepatite c et le virus de la dengue
CA2819548C (fr) 2010-12-10 2019-04-09 Sigmapharm Laboratories, Llc Compositions tres stables d'analogues nucleotidiques actifs par voie orale ou de promedicaments sous forme d'analogues nucleotidiques actifs par voie orale
ZA201103820B (en) 2010-12-13 2012-01-25 Laurus Labs Private Ltd Process for the preparation of tenofovir
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
ES2629913T3 (es) 2011-05-19 2017-08-16 Gilead Sciences, Inc. Procesos e intermediarios para la preparación de agentes anti-VIH
HUE031253T2 (en) * 2011-08-16 2017-07-28 Gilead Sciences Inc Tenofovir alafenamid hemifumarate
AU2014271320B2 (en) * 2011-08-16 2017-02-23 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
BR112014011340A2 (pt) * 2011-10-07 2017-06-13 Gilead Sciences Inc métodos para a preparação de análogos de nucleotídeos antivirais
AU2016228317B2 (en) * 2011-10-07 2018-07-19 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
AU2014215976B2 (en) * 2011-10-07 2016-06-30 Gilead Sciences, Inc. Methods for preparing anti-viral nucleotide analogs
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
US20150105350A1 (en) 2012-02-03 2015-04-16 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
WO2013115916A1 (fr) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Polythérapie comprenant le gs-7340 et le cobicistat destinée à être utilisée dans le traitement d'infections virales
CN107312039B (zh) * 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
GB201215696D0 (en) * 2012-09-03 2012-10-17 Ithemba Pharmaceuticals Pty Ltd A process for the preparation of (R)-9-[2-(Phosphonometh-Oxy)propyl]adenine (PMPA)
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
CN102899327B (zh) * 2012-11-06 2014-06-11 清华大学深圳研究生院 一种抗病毒的小核酸及其温度敏感型凝胶制剂与应用
EP2920171B1 (fr) * 2012-11-16 2018-08-29 Merck Sharp & Dohme Corp. Inhibiteurs puriques de la phosphatidylinositol 3-kinase delta humaine
CN103848868B (zh) * 2012-12-04 2017-04-12 蚌埠丰原涂山制药有限公司 制备替诺福韦的方法
CN103848869B (zh) * 2012-12-04 2016-12-21 上海医药工业研究院 制备替诺福韦的方法
LT2950786T (lt) 2013-01-31 2020-03-10 Gilead Pharmasset Llc Dviejų antivirusinių junginių preparatų kompozicija
CN104072539B (zh) * 2013-03-25 2017-03-29 安徽贝克联合制药有限公司 替诺福韦双(4‑乙酰氨基苯酚氧基)酯及其制备方法和其应用
WO2014187314A1 (fr) * 2013-05-21 2014-11-27 成都先导药物开发有限公司 Procédé de capture de cibles de médicaments
CA2914381A1 (fr) 2013-06-07 2014-12-11 Cipla Limited Procede efficace pour separer les diastereomeres de la 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]-adenine
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
WO2015040640A2 (fr) * 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
EP2860185A1 (fr) 2013-10-09 2015-04-15 Zentiva, k.s. Procédé amélioré pour la préparation du Ténofovir disoproxil et ses sels pharmaceutiquement acceptables
WO2015079455A2 (fr) * 2013-11-27 2015-06-04 Laurus Labs Private Limited Processus de recyclage permettant de préparer des diastéréoisomères de ténofovir alafénamide
WO2015107451A2 (fr) 2014-01-14 2015-07-23 Mylan Laboratories Ltd. Purification de ténofovir alafénamide et de ses intermédiaires
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
CN104804042B (zh) * 2014-01-24 2018-01-19 齐鲁制药有限公司 核苷酸膦酸酯类化合物、其药物组合物、制备方法及用途
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015127848A1 (fr) * 2014-02-27 2015-09-03 四川海思科制药有限公司 Dérivé de phosphoramidate substitué, sa méthode de préparation et ses utilisations
CN105001262B (zh) * 2014-04-18 2017-09-01 四川海思科制药有限公司 芳基取代的磷酰胺类衍生物及其在医学上的应用
WO2015161785A1 (fr) * 2014-04-21 2015-10-29 四川海思科制药有限公司 Procédé de préparation d'un dérivé phosphoramidate et de ses intermédiaires, et procédé de préparation d'intermédiaires
CN105085571A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 替诺福韦艾拉酚胺复合物及其制备方法和用途
WO2015197006A1 (fr) * 2014-06-25 2015-12-30 四川海思科制药有限公司 Composé thioester d'acide aminé substitué, et composition et application de celui-ci
JP2017520545A (ja) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド プロドラッグ化合物およびそれらの使用
CN106687467A (zh) * 2014-09-30 2017-05-17 韩美精密化学株式会社 高纯度（r）‑9‑[2‑（磷酰甲氧基）丙基]腺嘌呤的制备方法
KR101703258B1 (ko) 2014-12-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
KR101703257B1 (ko) 2014-09-30 2017-02-06 한미정밀화학주식회사 고순도의 (r)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
WO2016057866A1 (fr) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions et méthodes d'administration d'agents thérapeutiques
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
CN105646584B (zh) * 2014-11-12 2018-09-28 四川海思科制药有限公司 替诺福韦艾拉酚胺富马酸盐晶型及其制备方法和用途
CN104558036A (zh) * 2014-12-11 2015-04-29 杭州和泽医药科技有限公司 一种替诺福韦艾拉酚胺半反丁烯二酸盐晶型及其制备方法
US20170348334A1 (en) 2015-01-03 2017-12-07 Mylan Laboratories Limited Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof
WO2016187160A1 (fr) * 2015-05-16 2016-11-24 Godx, Inc. Dispositif d'analyse sur site et procédés d'utilisation associés
CN106188139B (zh) * 2015-05-29 2020-02-18 江苏天士力帝益药业有限公司 替诺福韦单苄酯磷酸酰胺前药、其制备方法及应用
CZ2015384A3 (cs) 2015-06-05 2016-12-14 Zentiva, K.S. Pevné formy Tenofovir alafenamidu
JP2018524308A (ja) * 2015-06-17 2018-08-30 ギリアード サイエンシーズ， インコーポレイテッド テノホビルアラフェナミドの共結晶、塩および結晶形態
EP3607939B1 (fr) 2015-06-30 2022-06-01 Gilead Sciences, Inc. Formulations pharmaceutiques comprenant tenofovir et emtricitabine
KR102163611B1 (ko) 2015-08-10 2020-10-08 머크 샤프 앤드 돔 코포레이션 항바이러스 베타-아미노산 에스테르 포스포디아미드 화합물
TWI616452B (zh) * 2015-08-26 2018-03-01 Preparation method of nucleoside analog and intermediate thereof
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
TWI616453B (zh) * 2015-08-27 2018-03-01 Substituted amino acid thioester compounds, compositions and uses thereof
WO2017037608A1 (fr) * 2015-08-28 2017-03-09 Laurus Labs Private Limited Formes solides de ténofovir alafénamide et sels associés, procédés pour leur préparation et compositions pharmaceutiques associées
PL3785717T3 (pl) 2015-09-16 2022-05-02 Gilead Sciences, Inc. Sposoby leczenia infekcji coronaviridae
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
CN106800573B (zh) * 2015-11-25 2020-03-10 四川海思科制药有限公司 一种核苷酸膦酸酯一水合物及其制备方法和在医药上的应用
WO2017100108A1 (fr) 2015-12-10 2017-06-15 Merck Sharp & Dohme Corp. Promédicaments antiviraux du ténofovir à base de phosphodiamide
CN106866737B (zh) * 2015-12-11 2020-11-20 南京圣和药物研发有限公司 膦酸衍生物及其应用
EP3390413B1 (fr) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Composés oximes phosphoramides antiviraux
WO2017118928A1 (fr) 2016-01-06 2017-07-13 Lupin Limited Procédé servant à la séparation de diastéréomères de ténofovir alafénamide
EP3411378B1 (fr) 2016-02-02 2020-03-25 Sandoz AG Forme cristalline du monofumarate de ténofovir alafénamide
CN107709288A (zh) * 2016-02-03 2018-02-16 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
WO2017148290A1 (fr) * 2016-03-01 2017-09-08 深圳市塔吉瑞生物医药有限公司 Composé d'adénine substituée et composition pharmaceutique correspondante
CN107179355B (zh) * 2016-03-11 2021-08-10 广东东阳光药业有限公司 一种分离检测替诺福韦艾拉酚胺及其有关物质的方法
CZ2016156A3 (cs) 2016-03-17 2017-09-27 Zentiva, K.S. Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí
CN107226826A (zh) * 2016-03-25 2017-10-03 江苏奥赛康药业股份有限公司 替诺福韦艾拉酚胺富马酸盐化合物及其药物组合物
CN109476689B (zh) 2016-06-05 2021-09-03 上海诚妙医药科技有限公司 富马酸替诺福韦艾拉酚胺盐的新晶型、制备方法及其用途
CN107698621A (zh) * 2016-06-20 2018-02-16 杭州和泽医药科技有限公司 一种腺嘌呤衍生物的膦酸酯前药及其在医药上的应用
WO2017221189A1 (fr) * 2016-06-22 2017-12-28 Laurus Labs Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
CN106317116A (zh) * 2016-08-19 2017-01-11 张红利 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
CN106380484A (zh) * 2016-08-29 2017-02-08 杭州百诚医药科技股份有限公司 一种替诺福韦艾拉酚胺的新晶型及其制备方法
WO2018042331A1 (fr) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
WO2018051250A1 (fr) 2016-09-14 2018-03-22 Viiv Healthcare Company Combinaison comprenant du ténofovir alafénamide, du bictégravir et du 3tc
EP3532069A4 (fr) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. Composés aryl-amide phosphodiamide antiviraux
CN106565785B (zh) * 2016-11-09 2019-11-12 周雨恬 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途
CN108129514A (zh) * 2016-12-01 2018-06-08 北京美倍他药物研究有限公司 磷酸/膦酸衍生物的单一异构体及其医药用途
AU2017379850B2 (en) 2016-12-22 2022-03-24 Msd International Gmbh Antiviral aliphatic ester prodrugs of tenofovir
KR20190100249A (ko) * 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 항바이러스 벤질-아민 포스포디아미드 화합물
WO2018115046A1 (fr) 2016-12-23 2018-06-28 Sandoz Ag Formes solides cristallines de ténofovir alafénamide
TWI784370B (zh) 2017-01-31 2022-11-21 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
WO2018153977A1 (fr) 2017-02-24 2018-08-30 Hexal Ag Composition stable de ténofovir alafénamide
RU2647576C1 (ru) * 2017-02-28 2018-03-16 Васильевич Иващенко Александр Циклобутил (S)-2-[[[(R)-2-(6-аминопурин-9-ил)-1-метил-этокси]метил-фенокси-фосфорил]амино]-пропаноаты, способ их получения и применения
RU2659388C1 (ru) 2017-02-28 2018-07-02 Васильевич Иващенко Александр Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение
CN106866739B (zh) * 2017-03-10 2018-11-02 华东师范大学 一种(r)-1-(6-氨基-9h-嘌呤-9-基)2-苯酯的制备方法
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CA3054822A1 (fr) 2017-03-20 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prophylaxie du vih post-exposition
CN108794530A (zh) * 2017-04-26 2018-11-13 上海医药工业研究院 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
KR102379965B1 (ko) * 2017-05-19 2022-03-29 주식회사 종근당 테노포비르의 효율적인 제조방법
CN107266499B (zh) * 2017-06-05 2019-07-02 珠海优润医药科技有限公司 一种抗病毒化合物及其制备方法
CN111587107B (zh) 2017-06-30 2023-03-31 希普拉有限公司 药物组合物
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
WO2019021319A1 (fr) 2017-07-27 2019-01-31 Cipla Limited Compositions pharmaceutiques
EP3661937B1 (fr) 2017-08-01 2021-07-28 Gilead Sciences, Inc. Formes crystallines d'éthyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)méthyl)(phénoxy)phosphoryl)-l-alaninate (gs-9131) pour le traitement des infections virales
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
CN107655987B (zh) * 2017-09-08 2020-11-03 厦门蔚扬药业有限公司 一种替诺福韦艾拉酚胺及其异构体的hplc检测方法
CN107522743A (zh) * 2017-09-30 2017-12-29 深圳科兴生物工程有限公司 一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
WO2019084020A1 (fr) 2017-10-24 2019-05-02 Gilead Sciences, Inc. Méthodes de traitement de patients co-infectés par un virus et la tuberculose
CN109942632B (zh) * 2017-12-20 2021-08-31 上海博志研新药物研究有限公司 替诺福韦艾拉酚胺中间体的制备方法
CN109942633B (zh) * 2017-12-20 2021-08-31 上海新礼泰药业有限公司 替诺福韦艾拉酚胺中间体的制备方法
WO2019130354A1 (fr) 2017-12-30 2019-07-04 Cipla Limited Formes polymorphes de (9-[(r)-2-[[(s)-[[(s)-1- (isopropoxycarbonyl)éthyl]amino]phénoxy phosphinyl]méthoxy]propyl]adénine et leurs sels pharmaceutiquement acceptables
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof
EP3752511A4 (fr) * 2018-01-10 2021-12-29 Nucorion Pharmaceuticals, Inc. Composés de phosphore(n)amidatacétal et phosph(on)atalcétal
WO2019140365A1 (fr) * 2018-01-12 2019-07-18 Board Of Regents Of The University Of Nebraska Promédicaments antiviraux et formulations de ceux-ci
CN111836805B (zh) 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
CA3175557A1 (fr) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methodes et intermediaires pour preparer un compose therapeutique utile dans le traitement d'une infection virale des retroviridae
CN108101943B (zh) * 2018-02-28 2020-11-24 顾世海 一种替诺福韦前药或可药用盐及其在医药上的应用
WO2019199756A1 (fr) 2018-04-09 2019-10-17 Board Of Regents Of The University Of Nebraska Promédicaments antiviraux et formulations de ceux-ci
CA3103522C (fr) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Inhibiteurs de capsides pour le traitement du vih
WO2020018399A1 (fr) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Promédicaments d'amide phosphinique de ténofovir
CN112996517A (zh) 2018-09-19 2021-06-18 吉利德科学公司 预防hiv的整合酶抑制剂
WO2021011891A1 (fr) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Formulations à action prolongée de ténofovir alafénamide
WO2021015818A1 (fr) 2019-07-19 2021-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prophylaxie pré-exposition du vih
WO2021034804A1 (fr) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Formulations pharmaceutiques de ténofovir alafénamide
KR20220083673A (ko) * 2019-08-22 2022-06-20 에모리 유니버시티 뉴클레오사이드 전구약물 및 이와 관련된 용도
US20220372171A1 (en) * 2019-09-20 2022-11-24 Abbott Rapid Diagnostics International Unlimited Company Antibody directed against tenofovir and derivatives thereof
CN114727999A (zh) 2019-11-26 2022-07-08 吉利德科学公司 用于预防hiv的衣壳抑制剂
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
EP4085062A1 (fr) 2020-02-20 2022-11-09 Cipla Limited Nouveaux sels et/ou co-cristaux de ténofovir alafénamide
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
TW202200161A (zh) 2020-03-20 2022-01-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
WO2021202669A2 (fr) 2020-04-01 2021-10-07 Reyoung Corporation Composés conjugués de nucléoside et de nucléotide et leurs utilisations
EP4132651A1 (fr) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano
KR20210125298A (ko) 2020-04-08 2021-10-18 주식회사 파마코스텍 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법
WO2021216427A1 (fr) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Composés de promédicaments nucléotidiques
CA3179226A1 (fr) 2020-05-29 2021-12-02 Tomas Cihlar Methodes de traitement par remdesivir
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
CA3181690A1 (fr) 2020-06-25 2021-12-30 Chienhung CHOU Inhibiteurs de capside pour le traitement du vih
CN113970612B (zh) * 2020-07-22 2023-08-01 北京四环制药有限公司 一种高效液相色谱法测定丙酚替诺福韦有关物质的方法
TW202233204A (zh) 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
CN112336695B (zh) * 2020-09-28 2023-01-03 华北制药华坤河北生物技术有限公司 一种富马酸丙酚替诺福韦片剂及其制备方法和有关物质的检测方法
WO2022103758A1 (fr) 2020-11-11 2022-05-19 Gilead Sciences, Inc. Procédés d'identification des patients vih sensibles à la thérapie avec des anticorps visant le site de liaison cd4 de la gp120
US11667656B2 (en) 2021-01-27 2023-06-06 Apotex Inc. Crystalline forms of Tenofovir alafenamide
CN113214322B (zh) * 2021-04-30 2022-10-25 山东立新制药有限公司 替诺福韦绿色环保的制备方法
WO2022251594A1 (fr) * 2021-05-27 2022-12-01 Antios Therapeutics, Inc. Pharmacocinétique et améliorations liées à la dose chez des sujets traités avec des promédicaments de phosphoramidate de clevudine
TW202342448A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
CN114369120A (zh) * 2022-01-28 2022-04-19 石家庄龙泽制药股份有限公司 一种丙酚替诺福韦关键中间体的制备方法
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202400165A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (fr) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Régime de dosage et de planification pour anticorps largement neutralisants
WO2024076915A1 (fr) 2022-10-04 2024-04-11 Gilead Sciences, Inc. Analogues de 4'-thionucléosides et leur utilisation pharmaceutique

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS233665B1 (en) 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
US5057301A (en) 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5053215A (en) * 1988-05-26 1991-10-01 University Of Florida NMR-assayable ligand-labelled trifluorothymidine containing composition and method for diagnosis of HSV infection
US5744600A (en) 1988-11-14 1998-04-28 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Phosphonomethoxy carbocyclic nucleosides and nucleotides
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
JP2648516B2 (ja) 1989-07-27 1997-09-03 ダイセル化学工業株式会社 立体異性体の分離法
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
JP2925753B2 (ja) 1990-02-23 1999-07-28 ダイセル化学工業株式会社 光学異性体の分離方法
DE69110528T2 (de) * 1990-04-20 1996-03-14 Acad Of Science Czech Republic Chirale 2-(Phosphonomethoxy)propyl-Guanine als antivirale Agentien.
US5302585A (en) 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
SK280313B6 (sk) 1990-04-24 1999-11-08 �Stav Organick� Chemie A Biochemie Av �R N-(3-fluór-2-fosfonylmetoxypropyl)deriváty purínov
US5627165A (en) * 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
CS387190A3 (en) 1990-08-06 1992-03-18 Ustav Organicke Chemie A Bioch (2r)-2-/di(2-propyl)phosphonylmethoxy/-3-p-toluenesulfonyloxy -1- trimethylacetoxypropane and process for preparing thereof
CA2088363C (fr) 1990-08-10 2002-05-28 Purushotham Vemishetti Methode de preparation de nucleotides
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5208221A (en) * 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
CZ284678B6 (cs) 1991-05-20 1999-01-13 Ústav Organické Chemie A Biochemie Avčr Di(2-propyl)estery 1-fluor-2-fosfonomethoxy-3-p -toluensulfonyloxypropanů, způsob jejich přípravy a použití
JP3010816B2 (ja) 1991-08-22 2000-02-21 ダイセル化学工業株式会社 光学分割における光学異性体と溶媒との回収方法、溶媒の循環使用方法、および光学異性体の再利用方法
US5498752A (en) 1991-08-22 1996-03-12 Daicel Chemical Industries, Ltd. Process for recovering optical isomers and solvent, process for using solvent by circulation and process for reusing optical isomers in optical resolution
AU661347B2 (en) 1991-10-11 1995-07-20 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
EP0719273B1 (fr) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Analogues de nucleotides
US5656745A (en) * 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
AU690587B2 (en) * 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US5977061A (en) 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
CA2222048A1 (fr) * 1995-05-26 1996-11-28 Polska Akademia Nauk Compositions et methodes de synthese de derives organophosphores
CA2239020A1 (fr) 1995-12-29 1997-07-10 Norbert W. Bischofberger Analogues de nucleotides
US5717095A (en) * 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
US5874577A (en) * 1996-04-03 1999-02-23 Medichem Research, Inc. Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
CA2261619C (fr) * 1996-07-26 2006-05-23 Gilead Sciences, Inc. Analogues de nucleotides
US5739314A (en) 1997-04-25 1998-04-14 Hybridon, Inc. Method for synthesizing 2'-O-substituted pyrimidine nucleosides
CA2596320C (fr) 1997-07-25 2008-12-23 Gilead Sciences, Inc. Compositions d'analogue de nucleotide
ID24701A (id) 1997-07-25 2000-08-03 Gilead Sciences Inc Komposisi dan metode sintesis analog nukleotida
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
WO1999030727A1 (fr) * 1997-12-17 1999-06-24 Enzon, Inc. Prodrogues polymeriques d'agents bioactifs contenant amine ou hydroxy
WO1999037753A1 (fr) * 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
AU755564B2 (en) * 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6169879B1 (en) * 1998-09-16 2001-01-02 Webtv Networks, Inc. System and method of interconnecting and using components of home entertainment system
GB9821058D0 (en) † 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
TWI230618B (en) 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
PL204458B1 (pl) † 1999-02-12 2010-01-29 Univ Cardiff Pochodne fosforanowe (1R,cis)-4-(6-amino-9H-puryn-9-ylo)-2-cyklopenteno-1-metanolu, kompozycje zawierające te związki, sposób wytwarzania tych związków oraz ich zastosowanie
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
CA2425610A1 (fr) * 2000-10-13 2002-04-18 University Of Lausanne Liberation intracellulaire d'effecteurs biologiques
US20020119433A1 (en) * 2000-12-15 2002-08-29 Callender Thomas J. Process and system for creating and administering interview or test

Also Published As

Publication number Publication date
DK1301519T4 (da) 2021-12-20
HUP0301307A3 (en) 2005-12-28
NL300803I2 (fr) 2016-06-30
FR16C0013I2 (fr) 2016-09-09
KR20030022295A (ko) 2003-03-15
BR0112646A (pt) 2003-06-24
ES2536972T5 (es) 2022-04-06
PL360490A1 (en) 2004-09-06
MXPA03000587A (es) 2004-04-05
NO20131717L (no) 2003-03-20
ZA200210271B (en) 2003-12-31
NO336718B1 (no) 2015-10-26
JP5063554B2 (ja) 2012-10-31
US20050124584A1 (en) 2005-06-09
CN1291994C (zh) 2006-12-27
WO2002008241A2 (fr) 2002-01-31
BG66037B1 (bg) 2010-11-30
IS2985B (is) 2017-09-15
NZ523438A (en) 2005-02-25
CA2416757A1 (fr) 2002-01-31
HRP20030047B1 (hr) 2016-02-26
AP2003002724A0 (en) 2003-06-30
AU8294101A (en) 2002-02-05
US20080227754A1 (en) 2008-09-18
AP1466A (en) 2005-09-22
CY1119411T1 (el) 2018-03-07
US20060024659A1 (en) 2006-02-02
ES2627903T3 (es) 2017-08-01
BG107572A (bg) 2003-11-28
FR16C0013I1 (fr) 2016-05-27
US20050124585A1 (en) 2005-06-09
HUP0301307A2 (hu) 2003-09-29
SI2682397T1 (sl) 2017-08-31
LT2682397T (lt) 2017-06-12
NZ535408A (en) 2006-09-29
CN100402539C (zh) 2008-07-16
PT2682397T (pt) 2017-05-31
JP4651264B2 (ja) 2011-03-16
AU2001282941C1 (en) 2016-12-22
CA2725819C (fr) 2015-09-22
EA004926B1 (ru) 2004-10-28
CY2016008I2 (el) 2016-12-14
TR200300055T2 (tr) 2004-12-21
JP2010174033A (ja) 2010-08-12
LTC1301519I2 (lt) 2023-02-27
AU2005225039A1 (en) 2005-11-10
CZ2003413A3 (cs) 2003-12-17
OA12393A (en) 2006-04-18
ES2536972T3 (es) 2015-06-01
HUS000494I2 (hu) 2021-03-29
US20050159392A1 (en) 2005-07-21
CA2416757C (fr) 2011-02-15
DK1301519T3 (en) 2015-05-26
UA75889C2 (uk) 2006-06-15
US20050009043A1 (en) 2005-01-13
LU93029I2 (fr) 2016-06-14
BRPI0112646B1 (pt) 2017-10-17
IS6689A (is) 2003-01-17
HRP20160074B1 (hr) 2021-09-03
NO2016006I2 (no) 2016-04-19
JP2009062383A (ja) 2009-03-26
CZ304886B6 (cs) 2015-01-07
AU2001282941B2 (en) 2006-04-27
US7803788B2 (en) 2010-09-28
CZ304734B6 (cs) 2014-09-10
JP2004504402A (ja) 2004-02-12
KR20060105807A (ko) 2006-10-11
DK2682397T3 (da) 2017-06-19
WO2002008241A3 (fr) 2002-08-29
EA200300188A1 (ru) 2003-06-26
JP2011140506A (ja) 2011-07-21
HU230960B1 (hu) 2019-06-28
HRP20030047A2 (en) 2007-08-31
HUS1900027I1 (hu) 2021-03-29
EE200300029A (et) 2004-10-15
NO20120466L (no) 2003-03-20
CA2725819A1 (fr) 2002-01-31
CA2893174A1 (fr) 2002-01-31
US20020119443A1 (en) 2002-08-29
LTPA2016009I1 (lt) 2016-04-25
NO20150909L (no) 2003-03-20
AU2005225039B2 (en) 2008-09-25
NO20030270D0 (no) 2003-01-20
NO2016006I1 (no) 2016-04-19
US7390791B2 (en) 2008-06-24
US20050124583A1 (en) 2005-06-09
EE05366B1 (et) 2010-12-15
EP1301519B1 (fr) 2015-02-25
KR100767432B1 (ko) 2007-10-17
CY2016008I1 (el) 2016-12-14
US20030219727A1 (en) 2003-11-27
US20040018150A1 (en) 2004-01-29
CN1706855A (zh) 2005-12-14
PL213214B1 (pl) 2013-01-31
IL153658A0 (en) 2003-07-06
EP1301519B2 (fr) 2021-11-10
HK1243711A1 (zh) 2018-07-20
HK1054238A1 (en) 2003-11-21
NO20030270L (no) 2003-03-20
PT1301519E (pt) 2015-06-11
KR100749160B1 (ko) 2007-08-14
NZ536942A (en) 2006-03-31
EP3235823A1 (fr) 2017-10-25
HRP20160074A8 (hr) 2016-07-29
HRP20160074A2 (hr) 2016-03-11
BRPI0112646B8 (pt) 2021-05-25
EP1301519A2 (fr) 2003-04-16
EP2682397B1 (fr) 2017-04-19
CN1443189A (zh) 2003-09-17
NO2023006I1 (no) 2023-02-03
JP5111551B2 (ja) 2013-01-09
SI1301519T1 (sl) 2015-07-31
EP2682397A1 (fr) 2014-01-08

Similar Documents

Publication Publication Date Title
BE2016C059I2 (fr)
BE2016C018I2 (fr)
BE2015C062I2 (fr)
BE2012C026I2 (fr)
BE2011C032I2 (fr)
BE2010C009I2 (fr)
JP2002538922A5 (fr)
JP2001255560A5 (fr)
IN2003CH00475A (fr)
JP2003511857A5 (fr)
JP2000325743A5 (fr)
JP2001003940A5 (fr)
CH694022C1 (fr)
BRPI0000763B8 (fr)
CN3143069S (fr)
CN3139842S (fr)
CN3145693S (fr)
CN3145461S (fr)
CN3145095S (fr)
CN3144928S (fr)
CN3144671S (fr)
CN3143879S (fr)
CN3143422S (fr)
CN3135640S (fr)
CN3147984S (fr)